VITROLIFE AB (PUBL) · VITROLIFE AB (PUBL) Danske Bank’s Copenhagen Winter Seminar 2018. Thomas...

21
VITROLIFE AB (PUBL) Danske Bank’s Copenhagen Winter Seminar 2018 Thomas Axelsson, CEO 1

Transcript of VITROLIFE AB (PUBL) · VITROLIFE AB (PUBL) Danske Bank’s Copenhagen Winter Seminar 2018. Thomas...

  • VITROLIFE AB (PUBL)

    Danske Bank’s Copenhagen Winter Seminar 2018

    Thomas Axelsson, CEO

    1

  • LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION

    2 * Rolling 12 months

    A Swedish company

    Founded in 1994

    Approx 370 employees

    Sales 1 102 MSEK*

    98 % on export

    Listed on NASDAQ Stockholm Mid Cap

  • THE IVF-PROCESS – VITROLIFE PRODUCTS

    3

    Hormonestimulation toincrease the number of retrievable eggs

    HORMONETREATMENT

  • AGE IS A CRITICAL FACTOR FOR SUCCESS

    4 2015 Assisted Reproductive Technology, National Center for Chronic Disease Prevention and Health Promotion, Divison ofReproductive Health

    Day 3 and Day 5 embryo transfers that resulted in live births by age

    Percentages of ART cycles that resulted in miscarriage by age

  • PRE-IMPLANTATION GENETIC TESTING

    PGT-a (aneuploidy)- previously named PGS (Screening)

    Testing whether the embryos are euploid (all 46 chromosomes)

    Aiding clinicians in order to choose which embryo to transfer

    PGT-m (monogenic)- previously named PGD (Diagnosis)

    Testing to avoid that a certain mutation (altered gene) is inherited to child

    Note: New applications, such as PGT-sr, looking at chromosomal rearrangements and PGT-p, looking at diseases caused by a large number of genes are emerging

    5

  • PGT-A WILL MATTER – MAINLY FOR OLDER PATIENTS

    6

    Percentage of euploid or normal embryos by age Miscarriage rate by maternal age

  • VERISEQ – OUR NEW OFFER IN PGT-A

    Amplification Library Prep Sequencing Software

    SurePlex WGA VeriSeq PGS BlueFuse Multi

    OEM kit from Rubicon-Takara*

    VeriSeq PGSlibrary prep

    VeriSeq PGSIndex Adapters

    MiSeq v3SBS Cartridge

    MiSeq PR2 Buffer

    MiSeq Flowcell

    Validated algorithms to call embryo status

    Clear visualization of genome

    Automated reports

    Note: Products are for research use only

    7

  • KARYOMAP12 - OUR OFFERING FOR PGT-M

    REPLI-g Single Cell Kit Karyomapping assay Scanning

    Laboratory purchases directly from QIAGEN

    Infinium protocol

    Hybridization

    Washing

    Staining

    Array loaded onto scanner for imaging

    Patented analysis algorithm

    Visualisation of results

    Reporting options

    8

    Amplification Library Prep Sequencing Software

    BlueFuse Multi

    Note: Products are for research use only

  • 9

    TREATMENTS & TECHNOLOGY THAT ARE INCREASING

    9

    Time-lapse Pre-implantation genetic testing Cryo-preservation

  • IMPROVED OUTCOMES USING TIME-LAPSE

    Frequently captured images of an embryo result in a video showing the development

    IMPROVED implantation rate 1-4 REDUCED pregnancy loss1, 5, 6 SHORTENED time to pregnancy 1

    1. Rubio et al (2014);Fertil Steril 102 (5):1287-1294 e1285. 2. Meseguer et al (2012); Fertil Steril 98 (6):1481-1489 e1410. 3. Kovacs et al (2013);Fertil Steril2013;100(3):S90. 4. Siristatidis (2015); J Assist Reprod Genet 5. Barrie et al (2013); Fertil Steril 100 (3):S248 6. Vitrolife metaanalysis of Kahraman et al (2013); J Reprod Stem Cell Biotechnol;3:55-61, Kovacs et al (2013) and Rubio et al (2014. )

    Artificial intelligence/deep learning algorithms tocreate automated objective embryo assessment tools

    10

  • EXPECTED SYNERGIES BETWEEN GENOMICS AND MORPHOLOGY

    Non-invasive PGT is yielding promising results - and could prove to offer advantages compared to trophectoderm biopsy

    Combining information from morphology and morphokinetics(time-lapse) could provide superior information when choosing what embryo to transplant

    Deep learning / AI algorithms could improve bioinformatics to interpret sequencing data

    Our leading position in time-lapse is an important asset in addressing these opportunities

    11

  • PRODUCTS AND SOFTWARE APPLICATIONS TO ALLOW SHORTERTIME TO PREGNANCY

    12

    Time-lapse

    Genetics Embryo selection Successful result

  • 13

    AGING EGGS AND CHROMOSOME ISSUES

    Source: US CDC/SART data

  • 14

    REASONS THAT EGG FREEZING WOMEN CHOSE TO DELAYCHILDBEARING

    0

    20

    40

    60

    80

    100

    Lack of partner Professionalreasons

    Financial reasons Too large of acommitment

    Other

    Source: ”What do reproductive age women who undergo oocyte cryopreservation think about the process as a meansto preserve fertility?” Fertility and Sterility

    88%

    24%15% 15%

    8%

    %

  • SUMMARY Q3

    15

    Sales of 284 MSEK (246) equals +15% in SEK

    Sales increased by 7% in local currency EBITDA of 121 MSEK (43% margin) Licensing and commercialization

    agreement with Illumina Inc., regarding preimplantation genetic testing after the end of the period

  • SALES AND GROWTH PER MARKET REGION

    16

    Total +7%

    Q3 GROWTH RATE COMPARED TO LAST YEAR IN LOCALCURRENCIES

    SHARE OF VITROLIFE’S SALESROLLING 12-MONTHS 14%

    +31%

    25%45%

    * Whereof organic growth +7 percent

    16%

    +4% +0%+3%

  • SALES AND GROWTH PER BUSINESS UNIT

    17

    +8%

    +4%

    +17%TIME-LAPSE

    DISPOSABLE DEVICES

    MEDIA

    ART EQUIPMENT

    Quarterly growthLocal currencies

    SEK millions, rolling 12m

    482 500 519 536 543 545 543 562584

    136 139 142148 150 148 151 149

    153148160 178

    209 233 254 271267 28220

    39 5678 80

    78 80 6561

    0

    200

    400

    600

    800

    1000

    1200

    Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3

    2016 2017

    -30%

    2018

  • GROWTH DRIVERS PER BUSINESS UNIT

    18

    SEK millions, rolling 12m

    2018

    Disposable Devices- Production capacity- Broaden portfolio

    ART Equipment- Regulatory approval- Sales activities- Sensor integration

    Time-lapse- Product offering- Support- Decision support / AI

    584

    153

    282

    61

    0

    200

    400

    600

    800

    1000

    1200

    Q3

    Media- R&D- User support- Cryo

  • SUMMARY

    19

    Broaden the product portfolio

    Time-lapse & genomics can give better clinical results

    Technology and treatments that are growing

    Good growth and high profitability

  • Contact: Thomas Axelsson, CEO, [email protected], +46 31 721 80 01Mikael Engblom, CFO, [email protected], +46 31 721 80 14

  • DISCLAIMER

    This presentation contains estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there is no assurance that these statements are correct or will be achieved. The most important strategic and operative risks regarding Vitrolife’s business and field are described in the Management report, in the Annual Report. These are primarily constituted by macro-economic risks, operational risks and financial risks.

    21

    Vitrolife aB (publ) leading company in medical �devices for assisted reproductionThe ivf-process – vitrolife productsAge is a critical factor for successPre-implantation genetic testingPGT-A will matter – MAINLY FOR older patientsVeriseq – our new offer in PGT-aKaryomap12 - our offering for PGT-MBildnummer 9Improved outcomes using time-lapseExpected synergies between genomics and morphologyProducts and Software applications to allow shorter time to pregnancyAging eggs and chromosome issuesReasons that egg freezing women chose to delay childbearingSummary Q3Sales and growth per market region�Sales and growth per business unitGrowth drivers per business unitsummary �Bildnummer 20Bildnummer 21